November 8, 2014
Notes: Endo, Justin O
Wong, Jillian W
Norman, Robert A
Chang, Anne Lynn S
Research Support, Non-U.S. Gov’t
J Am Acad Dermatol. 2013 Apr;68(4):521.e1-10; quiz 531-2. doi: 10.1016/j.jaad.2012.10.063.
Author Address: Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Reference Type: Journal Article
Record Number: 4443Author: Espana, A., Ornilla, E. and Panizo, C.
Title: Rituximab in dermatology
Journal: Actas Dermosifiliogr
Short Title: Rituximab in dermatology
Alternate Journal: Actas dermo-sifiliograficas
ISSN: 1578-2190 (Electronic)
Accession Number: 23665436
Keywords: Antibodies, Monoclonal, Murine-Derived/adverse effects/pharmacology/*therapeutic
Immunologic Factors/adverse effects/pharmacology/*therapeutic use
Skin Diseases/*drug therapy
Abstract: Rituximab was introduced into clinical practice as a medication with considerable potential. Its use in patients with B-cell lymphoma and rheumatoid arthritis revealed numerous indications in autoimmune diseases, many of which involve the skin, thus requiring dermatologists to become familiar with both the characteristics of anti-CD20 antibodies and the role of B cells in multiple skin diseases. Thanks to these developments, we will be able to use rituximab more frequently and appropriately in our patients and draw up consensus guidelines based on large case series. In other words, establishing the indications for rituximab will make it possible to shorten disease course and reduce morbidity due to more specific drugs.
Notes: Espana, A
Actas Dermosifiliogr. 2013 Jun;104(5):380-92. doi: 10.1016/j.adengl.2013.04.002. Epub 2013 May 10.
Author Address: Departamento de Dermatologia, Clinica Universidad de Navarra. Facultad de Medicina, Universidad de Navarra, Spain. email@example.com